Results 51 to 60 of about 141,530 (342)

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System

Journal of Pharmacological Sciences, 2010
The role of angiotensin II in mediating hypertension and renal diseases is well documented, and inhibition of the renin–angiotensin–aldosterone system elicits antihypertensive and renoprotective effects.
Akira Nishiyama, Koichi Hasegawa, Suwarni Diah, Hirofumi Hitomi   +3 more
doaj   +1 more source

The role of the angiotensins in the pathogenesis of inflammatory joint disease

Терапевтический архив, 2021
The significant humoral effect of the renin-angiotensin-aldosterone system on the regulation of the cardiovascular system and blood pressure has long been widely known. However, the identification and interpretation of new components of renin-angiotensin-
Andrei V. Gordeev, Elena A. Galushko, Natalia M. Savushkina   +2 more
doaj   +1 more source

Impaired angiotensin II signaling in septic shock

Annals of Intensive Care
Recent years have seen a resurgence of interest for the renin–angiotensin–aldosterone system in critically ill patients. Emerging data suggest that this vital homeostatic system, which plays a crucial role in maintaining systemic and renal hemodynamics ...
Adrien Picod, Bruno Garcia, Dirk Van Lier, Peter Pickkers, Antoine Herpain, Alexandre Mebazaa, Feriel Azibani   +6 more
doaj   +1 more source

RAA System and Exercise Relationship

Türk Spor ve Egzersiz Dergisi, 2019
In this review, it is aimed to discuss the possible interactions between renin-angiotensin-aldosterone system and exercise for health and performance and to present new literature on this subject.
Sadettin Ünsal, Suleyman Patlar
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Advances in Unraveling the Role of the Renin-Angiotensin-AldosteroneSystem in Osteoporosis Pathogenesis

Guoji laonian yixue zazhi
The renin-angiotensin-aldosterone system(RAAS) serves as a pivotal regulatory mechanism influencing aldosterone secretion through renin.Functioning as a hormonal cascade,RAAS plays a crucial role in maintaining dynamic homeostasis concerning arterial ...
Zige Liu, Desheng Chen
doaj   +1 more source

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Overview of Regulation of the Renin–Angiotensin–Aldosterone System

Journal of Pharmacological Sciences, 2010
The critical role played by the renin–angiotensin–aldosterone system (RAAS) in the regulation of blood pressure and body fluid homeostasis has been well recognized.
Akira Nishiyama, Shokei Kim-Mitsuyama
doaj   +1 more source

Renin-Angiotensin-Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA. [PDF]

, 2018
Background Mechanistic studies suggest that aldosterone impairs glucose metabolism. We investigated the cross-sectional associations of aldosterone and plasma renin activity with fasting plasma glucose, insulin resistance ( IR ), β-cell function, and ...
Allison, Matthew A, Echouffo Tcheugui, Justin B, Effoe, Valery S, Golden, Sherita H, Hsueh, Willa A, Joseph, Joshua J   +5 more
core   +1 more source

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19

New England Journal of Medicine, 2020
RAAS Inhibitors and Covid-19 The editors comment on three Journal articles that provide observational data about whether ACE inhibitors and ARBs are harmful in the context of the Covid-19 epidemic....
J. Jarcho, J. Ingelfinger, M. Hamel, R. D'Agostino, D. Harrington   +4 more
semanticscholar   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source